Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the...

Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020 LOS ANGELES, May 01, 2020 (GLOBE NEWSWIRE) -- Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc. The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split. LOS ANGELES, April 28, 2020 ...

Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...